Abstinent smokers may have reduced preoperative pain tolerance and increased postoperative opioid use compared with nonsmokers.
Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).
A longitudinal study assessed psychological status of postoperative patients with breast cancer between adjuvant chemotherapy for anxiety and depression.
A reduced risk of squamous cell carcinoma, but not basal cell carcinoma, was observed for one year in at-risk individuals treated with fluorouracil.
Using data from the TUS-CPS, researchers sought to determine the effect of pharmaceutical smoking cessation aids on long-term quit rates among patients who smoke tobacco.
The safety of breast implants has not been confirmed despite widespread use.
Although dynapenia and weak HGS is associated with poor outcomes in patients with cancer, it is not routinely assessed in this population.
Recent studies have suggested that married patients experience a survival benefit for various cancers; marriage has been associated with earlier detection, undergoing treatment, as well as better economic status and social support.
SBRT provides excellent local control and an adequate safety profile, but there is a lack of data comparing SBRT to resection among patients eligible for surgery.
FDA grants Breakthrough Therapy designation for ribociclib as an initial endocrine-based therapy for HR+/HER2- breast cancer in premenopausal or perimenopausal women.
Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.
Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.
Individuals with a history of atopic dermatitis have a higher risk of squamous cell carcinoma development, research indicates.
Coffee consumption was found to be generally safe and more likely to benefit health than harm.
In an effort to find alternatives to cisplatin as a radiation sensitizer, due to its dose-dependent toxicity and resistance, researchers are exploring food-based options such as blueberry extract.
Researchers examined the impact of BEAT Cancer intervention on sleep for breast cancer survivors.
For this meta-analysis and systematic review, investigators compiled phase 1 to 3 prospective clinical trials of carfilzomib therapy for patients with MM that had evaluable toxic effects data.
Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.
Evidence from previous studies for patients with ovarian and endometrial cancers has suggested that goshajinkigan may treat and prevent CIPN.
Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.
Adverse event rates were similar in both trial groups, though patients treated with TTFields were much more likely to have mild to moderate skin toxicity.
The US FDA approved pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of HER2-positive early breast cancer, and converted accelerated to full approval for the regimen as neoadjuvant therapy in certain breast cancers.
In the IMvigor 311 trial, researchers sought to determine if atezolizumab improves overall survival for patients with metastatic urothelial carcinoma vs physicians' choice of 3 IV regimens.
Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Using a series of functional tests, researchers determined the significance of sarcopenia severity after chemotherapy in older patients with cancer and its effect on their physical independence.
An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.
In a retrospective study of SEER-Medicare data, researchers determined the survival outcomes of women with breast cancer and comorbid mental illness vs those without mental illness.
Individuals categorized as overweight or obese had a significantly increased risk for malignant melanoma.
A survey of 754 cancer survivors sought to determine the association between number of neurotoxicities such as CIN, hearing loss, and tinnitus and outcomes for these patients.
The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.
Two studies evaluate use of deep learning algorithm; one for breast cancer, the other for diabetic retinopathy
Multimodal screening is more expensive, but reduces ovarian cancer mortality, researchers found.
For this study, researchers sought to determine the effect exercise would have on severity of symptoms for patients who develop CIPN after taxane, platinum, or vinca alkaloid based chemotherapy.
Postmenopausal women with weight gain had increased risk of triple-negative breast cancer, research indicates.
A survey of pediatric oncology providers including physicians, nurses, and social workers reveals their willingness to consider medical marijuana for children with cancer, as well as their reasons against its use in these patients.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.
A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.
Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.
Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.
A retrospective analysis of patients with CML determined prevalence of arterial thrombotic events in those receiving nilotinib as first-line treatment and prevalence by patient age. Data were presented at ASH 2017.
Data presented at ASH 2017 illustrates the effectiveness of 2 prophylactic antiemetic regimens in pediatric patients receiving moderately or highly emetogenic chemotherapy.
Trial investigates which of 3 maintenance regimens of nab-paclitaxel has the most ideal impact on quality of life in patients with metastatic breast cancer. Results were presented at SABCS 2017.
A study from French researchers identified which people are the most likely to influence a breast cancer patient's decision whether to undergo breast reconstruction. These findings were presented at SABCS 2017.
A team from Methodist Hospital Cancer Center discuss an app developed at the facility that helps breast cancer survivors with nutrition and physical activity at SABCS 2017.
Groups urge Congress to take immediate action, provide transparency, and improve drug manufacturing.
A single-center analysis demonstrates likelihood that mastalgia indicates presence of breast cancer and extensiveness of common work-up for the complaint. These findings were presented at SABCS 2017.
A team from Dana-Farber Cancer Institute describe EMBRACE, their comprehensive care program for patients with metastatic breast cancer at SABCS 2017.
Results of a study evaluating the effectiveness of bioimpedance spectroscopy in reducing incidence of chronic breast cancer-related lymphedema (BCRL) in high-risk patients with breast cancer were presented at SABCS 2017.
Researchers presented an update of findings in the GeparSepto trial, which seeks to determine whether improvements in pathologic complete response can be translated to a survival benefit, at SABCS 2017.
Novel weight reduction plan helps breast cancer survivors achieve and maintain a healthy weight and glucose level, according to a presentation at SABCS 2017.
A review of 12 antiemetic regimens identified 3 that may be more effective than conventional regimens, a study presented at SABCS 2017 has shown.
An approach for incorporating palliative care into oncologic care early after diagnosis is explained in an education session at the 2017 SABCS.
Ogivri was granted FDA approval to treat HER2 breast and gastric or gastroesophageal junction adenocarcinoma cancers.
A comparison study presented at the 2017 SABCS sought to determine the effectiveness of bisphosphonates with denosumab for skeletal-related events in women with breast cancer metastases to bone.
Choosing the optimal adjuvant therapy option for a patient with early-stage HR-positive breast cancer should be a continuous discussion with the patient, according to a presentation at SABCS 2017.
Using a mouse model of HER2+ breast cancer, researchers tested the efficiency of combined epigenetic modulation and checkpoint inhibition using the histone deacetylase inhibitor ENT and antibodies for 2 checkpoint inhibitor proteins. These findings were presented at the 2017 SABCS.
A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.
Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.
Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.
Despite advancements in treatment of CML, many patients still experience adverse effects of their disease and treatments. Therefore, researchers conducted a survey of patients to determine whether they felt assistance and support met their needs.
Papillary thyroid cancer patients with LND 0.19 have worse disease-specific, overall survival, researchers found.
Researchers conducted a geriatric assessment of 304 patients with cancer, then followed them in a 2-year study to determine the risk of fractures and falls in older patients.
Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.
Periodontal pathogen Tannerella forsythia linked to increased risk of esophageal adenocarcinoma
A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.
In a small but meaningful number of patients, Gleason pattern 4 disease missed by MRI and systematic biopsy is present outside the focal ablation zone.
A phase 2, randomized study investigated the effectiveness of oral curcumin, a component of turmeric, in reducing radiation dermatitis severity in patients undergoing radiation therapy for breast cancer.
Breast cancer was previously thought to not be immunogenic in nature, but a subset of patients with breast cancer, primarily with triple negative disease, have exhibited robust levels of tumor infiltrating leukocytes.
As more rare cancers are identified, the need for rethinking approaches to research will become greater.
A feasibility study involving 60 patients with bladder cancer sought to determine if preoperative vigorous cardiovascular activity would improve postsurgical outcomes.
Researchers conducted a review of more than 400 patients with hormone receptor-positive breast cancer to determine if high Oncotype DX RS is associated with a greater likelihood the cancer is hereditary.
Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.
Seventy percent of Americans surveyed in this year's National Cancer Opinion Survey were unaware that alcohol is a well-established and modifiable risk factor for cancer, the authors noted.
Results of this randomized, phase 3 study comparing oral gefitinib with IV vinorelbine plus cisplatin revealed the effect of these regimens on disease-free survival in patients with exon 19 deletion or exon Leu585Arg NSCLC.
Biomarker analysis revealed markers for cardiotoxicity enabling early initiation of heart failure therapy in patients with breast cancer who were treated with chemotherapy.
In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.
Young patients with chronic ITP may experience relapse within 5 years of completing therapy. In this study, investigators sought to determine if the 4R+3Dex regimen for chronic ITP would improve response rates in pediatric patients with the disease.
Hypogonadal men who received testosterone replacement therapy had a lower incidence of prostate cancer than those who did not, and their cancers were less severe.
Breakthrough Therapy Designation was granted for bb2121, a novel CAR T-cell therapy indicated for patients with multiple myeloma who have undergone previous treatments.
Using the statewide Utah Population Database, investigators sought to determine the long-term effects of thyroid cancer on survivors who were younger than 40 years at diagnosis.
Results of an open-label study demonstrated the effectiveness of loratadine in the management of bone pain in patients with breast cancer undergoing chemotherapy and receiving supportive therapy with pegfilgrastim.
Research presented at SABCS 2017 demonstrated the effect of refining the linear predictor for determining which patients with breast cancer would potentially benefit from adjuvant chemotherapy.
A retrospective analysis presented at 2017 SABCS reveals the factors that indicate a higher risk of developing brain metastases for women with HER2+ breast cancer.
Study findings presented at SABCS 2017 demonstrate that intermediate Oncotype DX scores are prognostic of overall survival for patients with early-stage breast cancer, particularly in younger women with the disease.
Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.
Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.
Clinicians and patients use this technology to monitor health, behaviors, and treatment outcomes.
Alcohol-related cancers account for 5.5 percent of all cancers treated annually worldwide.
Patients with early-stage breast cancer treated with aromatase inhibitors often experience adverse events that lead to discontinuation. In this phase 3 study, researchers sought to determine if duloxetine could manage these symptoms.
Researchers investigated the incidence of lymphedema on patients with breast cancer treated with TAC after axillary lymph node dissection (ALND), with or without radiotherapy, and its impact on quality of life for patients.
Lomustine plus bevacizumab may increase progression-free, but not overall, survival versus lomustine alone in progressive glioblastoma.
Just over half of patients in a standard therapy group had normal bone mineral density after a mean follow-up of 6 years; this contrasted with 93% of patients in a vitamin D supplementation group.
Follow-up of a 2-year analysis of the ExteNET phase 3 study demonstrates the influence of 1-year extended adjuvant therapy with neratinib on relapse in patients with breast cancer 5.2 years after treatment.
In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.
The impact of prostate cancer treatment is well documented; however, in this study, researchers sought to determine the effect on health-related quality of life for patients from diagnosis through treatment planning to initiation of treatment.
Data on psychosocial and psychiatric variables of patients with HNC prior to treatment was analyzed to determine the extent of cognitive impairment and quality of life for patients with head and neck cancer, and its impact on patient outcomes.
Women with ER-positive BC who stop therapy after 5 years have steady recurrence rate up to 20 years afterward.
An analysis of an intervention arm of the PLCO Cancer Screening Trial evaluated the risk of prostate cancer relative to dietary consumption of isoflavones, a dietary compound found in some plant foods.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Comparison of Survival Outcomes Between Radical Hysterectomy and Definitive Radiochemotherapy in Stage IB1 and IIA1 Cervical Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|